Breaking News, Collaborations & Alliances

NorthX and Demeetra Align to Accelerate Biotech Company Milestones

The collaboration combines a best-in-class, high-titer cell line with full freedom to operate and no intellectual property-related costs.

Author Image

By: Patrick Lavery

Content Marketing Editor

NorthX Biologics and Demeetra launched a strategic collaboration to help biotech companies reach Investigational New Drug (IND) and clinical milestones faster. The partnership combines a best-in-class glutamine synthetase (GS) (-/-) Chinese hamster ovary (CHO) cell line with full freedom to operate. Additionally, there are no intellectual property-related costs. Other advantages of the collaboration include advanced cell line development technologies and high-quality process development. M...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters